cefzil and Staphylococcal-Infections

In a randomized multicenter study, the efficacy and safety of cefprozil were compared with those of penicillin in the treatment of group A streptococcal tonsillopharyngitis in children. Of the 409 patients enrolled, 323 were evaluable for their clinical and bacteriological responses; of these 323 children, 172 received cefprozil and 151 received penicillin V. The clinical responses in patients treated with cefprozil were significantly better than those in patients who received penicillin (95.3 versus 88.1%; P = 0.023). Eradication of the original serotype of group A streptococci was achieved in 91.3% of patients treated with cefprozil and 87.4% of patients treated with penicillin, the difference not being statistically significant (P = 0.125). However, there were significantly more symptomatic patients among the bacteriological failures in the penicillin group (68.4%) than in the cefprozil group (26.7%). beta-Lactamase-producing Staphylococcus aureus was more frequently isolated from the throat flora during penicillin therapy than during cefprozil treatment. No difference in the incidence of adverse events probably related or of unknown relationship to the study drugs was observed in the two treatment groups (5.2% of those treated with cefprozil and 6.0% of those treated with penicillin). Cefprozil can be considered a safe and reliable drug for the treatment of streptococcal pharyngitis in children.

Topics: beta-Lactamases; Cefprozil; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Penicillin V; Pharyngitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus; Tonsillitis

Topics: Bacterial Infections; Cefaclor; Cefprozil; Cephalosporins; Child; Child, Preschool; Female; Humans; Male; Prospective Studies; Skin Diseases, Infectious; Staphylococcal Infections; Streptococcal Infections; Streptococcus pyogenes

40 patients with exacerbation of a chronic maxillary sinusitis were examined. Sinus puncture was performed (sinoject) in all of the patients. Before the treatment (500 mg cefprozil orally twice a day, the recommended duration of therapy was ten days) and on the fifth day, the microorganisms from sinus were isolated (the bacteriological culture, antibiogram and MIC were determined). On the second and the fifth day, blood cefprozil level and the presence of cefprozil in the washings from maxillary sinuses were investigated.. 17 pathogens were isolated from maxillary sinuses, only two of them were anaerobic. The bacterial strains: Staphylococcus (55%), E.coli (15%), Klebsiella (10%) and 20% of others, were found. Four of them (23.5%) were resistant to cefprozil. In all patients cefprozil was identified in maxillary sinuses (0.87-2.52 ug/ml). The value of MIC were from 0.094 to 2.0 ug/ml. A satisfactory clinical response was observed in 92.5% persons but the eradication of pathogens was obtained in 70%. The adverse clinical events (diarrhea) were observed only in one patient (2.5%).. cefprozil well penetrates into inflammable mucous membrane of maxillary sinuses. Cefprozil obtains efficient bactericidal concentration in relation to sensitive bacteria on the fifth day of therapy. It is also well tolerated by the patients.

Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefprozil; Cephalosporins; Chronic Disease; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Male; Maxillary Sinusitis; Microbial Sensitivity Tests; Middle Aged; Staphylococcal Infections; Treatment Outcome

Topics: Administration, Oral; Bacterial Infections; Biopsy, Needle; Bone Diseases; Cefprozil; Cephalosporins; Child; Child, Preschool; Humans; Joint Diseases; Joints; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus

In order to examine the in vivo activity of BMY-28100, serial quantitative nasal cultures were taken from 52 nasal carriers of Staphylococcus aureus following administration of the antimicrobial. Nasal carriage rates and mean log titers decreased significantly during (days 2-4 and 5-8) and following (days 1-2 and 6-7) treatment. No change in antibiotic sensitivities was noted in follow-up isolates, and the MIC90 remained at 2mcg/ml. BMY-28100 demonstrated good in vivo activity against Staphylococcus aureus.

Topics: Adult; Carrier State; Cefprozil; Cephalosporins; Humans; Male; Nasal Cavity; Staphylococcal Infections; Staphylococcus aureus